Gefitinib
Small molecule targets EGFR via inhibition
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Iressa | — | 2009-06-24 | europa.eu ↗ |
| Approved | US (FDA) | IRESSA | — | 2003-05-05 | fda.gov ↗ |
Trials 282 · started per year
Also used as a comparator or background therapy in 67 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 18 trials | ||||||
| Phase 1 | NCT07271446 Background | Sep 2018 → Aug 2019 | non-small cell lung carcinoma | Precision Biotech Taiwan Corp. | Completed | No outcome recorded |
| Phase 1 | NCT03050411 Background | May 2016 → Jun 2019 | non-small cell lung carcinoma | Peking University Third Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT02321293 Background | Aug 2015 → Aug 2016 | lung cancer | Lady Davis Institute | Unknown | No outcome recorded |
| Phase 1 | NCT01602289 Background | Jun 2012 → Aug 2014 | lymphoma, non-small cell lung carcinoma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01147211 Background | Sep 2010 → Jul 2013 | non-small cell lung carcinoma | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT00502060 Background | Aug 2004 → Jun 2006 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00310154 Background | Nov 2003 → Jul 2007 | lung cancer | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 1 | NCT00084708 Background | Nov 2002 → Oct 2006 | cancer of unknown primary site | Roswell Park Cancer Institute | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT03799094 Background | Dec 2018 → Dec 2020 | non-small cell lung carcinoma | Clifford Hospital, Guangzhou, China | Unknown | No outcome recorded |
| Phase 1/2 | NCT02906163 Background | Oct 2016 → Dec 2019 | lung cancer | SciClone Pharmaceuticals | Unknown | No outcome recorded |
| Phase 1/2 | NCT01039948 Comparator | Dec 2009 → Aug 2013 | non-small cell lung carcinoma | AVEO Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 225 trials | ||||||
| Phase 2 | NCT04425187 Comparator | Jun 2020 → Dec 2021 | — | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT03389256 Background | Dec 2018 → Dec 2020 | non-small cell lung carcinoma | Sichuan Cancer Hospital and Research Institute | Unknown | No outcome recorded |
| Phase 2 | NCT03461185 Background | May 2018 → Aug 2019 | non-small cell lung carcinoma | Xinqiao Hospital of Chongqing | Unknown | No outcome recorded |
| Phase 2 | NCT03119519 Background | Dec 2017 → Sep 2020 | non-small cell lung carcinoma | Southern Medical University, China | Unknown | No outcome recorded |
| Phase 2 | NCT03123484 Background | Apr 2017 → Apr 2019 | non-small cell lung carcinoma | China Medical University, China | Unknown | No outcome recorded |
| Phase 2 | NCT03595644 Background | Feb 2017 → Jun 2019 | non-small cell lung carcinoma | Tongji Hospital | Completed | No outcome recorded |
| Phase 2 | NCT03002844 Background | Dec 2016 → Aug 2017 | non-small cell lung carcinoma | Shanghai Pulmonary Hospital, Shanghai, China | Unknown | No outcome recorded |
| Phase 2 | NCT02788058 Background | May 2016 → May 2021 | lung adenocarcinoma | First People's Hospital of Hangzhou | Unknown | No outcome recorded |
| Phase 2 | NCT02787447 Background | May 2016 → Dec 2017 | lung adenocarcinoma | First People's Hospital of Hangzhou | Unknown | No outcome recorded |
| Phase 2 | NCT01864681 Background | May 2013 → Dec 2017 | cancer of unknown primary site, non-small cell lung carcinoma | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Completed | No outcome recorded |
| Phase 2 | NCT01556191 Background | May 2012 → May 2018 | — | French Cooperative Thoracic Intergroup | Completed | No outcome recorded |
| Phase 2 | NCT01610336 Background | Apr 2012 → Jun 2016 | non-small cell lung carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01502202 Comparator | Mar 2012 → Aug 2014 | adenocarcinoma, non-small cell lung carcinoma | National Cancer Center, Korea | Unknown | No outcome recorded |
| Phase 2 | NCT01466660 Comparator | Dec 2011 → Apr 2016 | lung neoplasm | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT01498562 Comparator | Dec 2011 → Jun 2014 | non-small cell lung carcinoma | Yonsei University | Completed | No outcome recorded |
| Phase 2 | NCT01310855 Comparator | May 2011 → May 2013 | glioblastoma | University College, London | Terminated | No outcome recorded |
| Phase 2 | NCT00891579 Comparator | Feb 2009 → Sep 2012 | non-small cell lung carcinoma | Chinese Society of Lung Cancer | Completed | No outcome recorded |
| Phase 2 | NCT01783834 Comparator | Feb 2008 → Jun 2014 | — | Gachon University Gil Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT01037998 Comparator | Nov 2005 → Dec 2009 | non-small cell lung carcinoma | Taipei Veterans General Hospital, Taiwan | Completed | No outcome recorded |
| Phase 2 | NCT00238251 Comparator | May 2005 → Apr 2009 | lung cancer, metastatic malignant neoplasm | Swiss Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT00479089 Comparator | Feb 2004 → Aug 2014 | urinary bladder cancer | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 2 | NCT00080743 Comparator | Jan 2004 → Apr 2005 | breast cancer | Dartmouth-Hitchcock Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00077025 Comparator | Jan 2004 → May 2013 | breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00025675 Comparator | Oct 2001 → Jul 2006 | central nervous system neoplasm | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 2 | NCT02184325 Comparator | Nov 1999 → Feb 2000 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT03653546 Comparator | Oct 2018 → Jul 2022 | metastatic malignant neoplasm in the brain, non-small cell lung carcinoma | Alpha Biopharma (Jiangsu) Co., Ltd. | Completed | No outcome recorded |
| Phase 2/3 | NCT02387086 Background | May 2015 → May 2017 | non-small cell lung carcinoma | Bai Jun | Unknown | No outcome recorded |
| Phase 321 trials | ||||||
| Phase 3 | NCT03866499 Comparator | Apr 2021 → Nov 2023 overdue | non-small cell lung carcinoma | Beta Pharma Shanghai | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04248829 Comparator | Feb 2020 → Jul 2022 | non-small cell lung carcinoma | Yuhan Corporation | Completed | No outcome recorded |
| Phase 3 | NCT04239833 Comparator | Jan 2020 → Jan 2022 | non-small cell lung carcinoma | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT03787992 Comparator | May 2019 → Sep 2021 overdue | — | Allist Pharmaceuticals, Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04028778 Background | Apr 2019 → Dec 2020 | non-small cell lung carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 3 | NCT03856697 Comparator | Mar 2019 → Mar 2022 | non-small cell lung carcinoma | Hangzhou ACEA Pharmaceutical Research Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT03849768 Comparator | Feb 2019 → Jan 2021 | non-small cell lung carcinoma | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT03529084 Comparator | Jul 2018 → Aug 2020 | non-small cell lung carcinoma | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 3 | NCT02824458 Background | Jun 2016 → Dec 2023 | — | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 3 | NCT02588261 Comparator | Feb 2016 → Dec 2017 | non-small cell lung carcinoma | Astellas Pharma Global Development, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT02893332 Background | Jan 2016 → Aug 2020 | lung cancer susceptibility 4 | Sichuan Provincial People's Hospital | Terminated | No outcome recorded |
| Phase 3 | NCT02882984 Background | Mar 2015 → Mar 2020 | — | Sichuan Provincial People's Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT02296125 Comparator | Dec 2014 → Jun 2017 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT01774721 Comparator | May 2013 → Jul 2016 | lung cancer | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT02889692 Background | Mar 2013 → Dec 2016 | cancer | Shanghai University of Traditional Chinese Medicine | Completed | No outcome recorded |
| Phase 3 | NCT01158170 Background | Jun 2010 → May 2013 | non-small cell lung carcinoma | Zhejiang Cancer Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT01017874 Comparator | Nov 2009 → Apr 2013 | non-small cell lung carcinoma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01024413 Comparator | Jul 2009 → Jun 2015 | neoplasm of thorax | Chinese Society of Lung Cancer | Completed | No outcome recorded |
| Phase 3 | NCT00955695 Background | May 2009 → ? | lung cancer | National Cancer Center, Korea | Unknown | No outcome recorded |
| Phase 3 | NCT01040780 Comparator | Feb 2009 → Mar 2010 | non-small cell lung carcinoma | Betta Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT00352079 Comparator | Jan 2007 → Jan 2012 | bladder transitional cell carcinoma | NCIC Clinical Trials Group | Terminated | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT04401059 Comparator | Nov 2020 → Sep 2025 | adenocarcinoma, non-small cell lung carcinoma | Tian Xie | Unknown | No outcome recorded |
| Phase not applicable7 trials | ||||||
| — | NCT04007835 Background | Jul 2019 → Jul 2021 | non-small cell lung carcinoma | Guangdong Association of Clinical Trials | Unknown | No outcome recorded |
| — | NCT03602027 Background | Aug → Dec 2018 | non-small cell lung carcinoma | Second Affiliated Hospital of Nanchang University | Unknown | No outcome recorded |
| — | NCT03071705 Background | Mar 2016 → Apr 2017 | lung adenocarcinoma | National Cancer Institute of Mexico | Unknown | No outcome recorded |
| — | NCT02701231 Background | Nov 2015 → Dec 2020 | lung cancer | Chinese PLA General Hospital | Unknown | No outcome recorded |
| — | NCT02208583 Comparator | Jun 2014 → Dec 2016 | hormone-resistant prostate carcinoma | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| — | NCT01776684 Background | Jun 2012 → May 2014 | lung cancer | Samsung Medical Center | Unknown | No outcome recorded |
| — | NCT01363557 Background | Mar → Aug 2012 | lung adenocarcinoma, metastatic malignant neoplasm in the brain | Assistance Publique - Hôpitaux de Paris | Terminated | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2019-07-02 | Novartis Pharmaceuticals | Sandoz launches oncology generic gefitinib in 13 EU countries at loss of market exclusivity, expanding access to essential medicine novartis.com ↗ |
Evidence & citations 17 cited values
Every value below carries the sentence it was read from. 357 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | gefitinib | “Participants with epidermal growth factor receptor (EGFR) gene mutation will receive a drug called Gefitinib, which inhibits a protein called EGFR that is thought to be a key...” NCT02208583 ↗308“This is a phase I study of MK2206 (an AKT inhibitor)and gefitinib in nonsmall cell lung cancer patients who failed prior chemotherapy and epidermal growth factor...” NCT01147211 ↗ “Patients were randomly allocated to receive EGFR-TKIs (erlotinib hydrochloride, afatinib dimaleate, or gefitinib at standard dosage) plus metformin hydrochloride (500 mg twice...” PMID 31486833 ↗ Nov 2019 “The purpose of this protocol is to estimate the maximum tolerated dose of gefitinib in combination with fixed dose of irinotecan and vincristine in patients with refractory...” NCT00186979 ↗ “This study aims to determine effectiveness of Gefitinib (Iressa) in recurrent glioblastoma after standard treatment (surgery, radiationtherapy and at least a first line chemotherapy).” NCT00250887 ↗ “Gefitinib is an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) that has been widely used for the treatment of non-small cell lung cancer (NSCLC).” PMID 22237124 ↗ Jan 2012 “Combination Anastrozole-ZD1839 (Gefitinib, IRESSA™) in Postmenopausal Patients With Estrogen Receptor (ER) and/or Progesterone Receptor (PgR) Metastatic Breast Cancer” NCT00077025 ↗ “Gefitinib(Iressa,YiRuiKe), Erlotinib(Tarceva), Icotinib(Kaimeina), Osimertinib(Tagrisso), Almonertinib, Furmonertinib, etc.” NCT04401059 ↗ “Gefitinib blocks the function of epidermal growth factor receptor which is a key factor in stimulating liver cancer growth.” NCT00282100 ↗ “Standard EGFR-TKI(Gefitinib, erlotinib or icotinib) Gefitinib: 250mg po Qd Erlotinib: 150mg po Qd Icotinib: 125mg po tid” NCT03595644 ↗ “Standard platinum-based doublet chemotherapy or EGFR-TKI (Gefitinib or Erlotinib) alone, according to gene test.” NCT03119519 ↗ “Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.” NCT00258323 ↗ “Imatinib tablets, 125 mg tid po; gefitinib tablets, 250 mg qd po; erlotinib tablets, 150 mg qd po” NCT03389256 ↗ “if EGFR mutation is positive, (gefitinib, ecotinib, erlotinib）or ALK/ROS-1 positive（Crizotinib）” NCT04193007 ↗ “With sensitive result the first-line therapy will be Erlotinib/Gefitinib/Crizotinib.” NCT02701231 ↗ “small molecules such as gefitinib (Iressa [ZD1839]; AstraZeneca, Wilmington, DE).” NCT00173875 ↗ “Gefitinib 250mg po qd or Erlotinib 150mg po qd or Icotinib 125mg po tid” NCT02788058 ↗ “Gefitinib 250mg po qd or Erlotinib 150mg po qd or Icotinib 125mg po tid” NCT02787447 ↗ “Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid” NCT02714010 ↗ “Gefitinib 250mg/QD plus vorinostat D1\~7 \& D15-21 / QD q 4weeks” NCT01027676 ↗ “Gefitinib 250mg or Erlotinib 150mg medication, Once-Daily.” NCT03382795 ↗ “Gefitinib maintenance therapy versus Gefitinib monotherapy” PMID 26725183 ↗ Dec 2015 “EGFR-TKIs include but are not limited erlotinib, gefitinib” NCT03461185 ↗ “Drug: Trastuzumab Drug: Gefitinib Drug: Lapatinib” NCT03768375 ↗ “gefitinib will be administered 250mg/d ivgtt qd” NCT03258671 ↗ “Gefitinib is administered 250 mg once per day.” NCT04007835 ↗ “Pemetrexed (ALIMTA) and Gefitinib (IRESSA®)” NCT01066195 ↗ “Pemetrexed 500mg/m2 iv and Gefitinib 250 mg” NCT01579630 ↗ “gefitinib 250mg/QD po daily every 3 weeks” NCT00452244 ↗ “Fludarabine Gefitinib Gemcitabine HCl” NCT02551718 ↗ “Fluorouracil, Gefitinib, Gemcitabine” NCT02788201 ↗ “EGFR-TKI (gefitinib 250mg per day)” NCT03002844 ↗ “afatinib, gefitinib, erlotinib” NCT02906163 ↗ “EGFR-TKI (gefitinib)” NCT02859077 ↗ “Iressa (Gefitinib)” NCT00233636 ↗ “Iressa (Gefitinib)” NCT00233623 ↗ “ZD1839 (Gefitinib)” NCT00034879 ↗ “Gefitinib” NCT02142036 ↗ |
| Known as | Comparator product | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02184325 ↗ |
| Known as | CTTQ | “Gefitinib Tab 250 MG（CTTQ），From the 8th day of trial.” NCT03264794 ↗ |
| Known as | GEF | “with the EGFR signaling inhibitor gefitinib (GEF) combined with weekly intravenous paclitaxel (PAC) and radiation therapy (RT).” PMID 19879702 ↗ Oct 2009 |
| Known as | Gefitinib (Iressa) | “Gefitinib (Iressa)” NCT01749072 ↗ |
| Known as | Gefitinib mylan | ChEMBL registry synonym — accepted as the source's own label CHEMBL939 ↗ |
| Known as | GFT | “patients with BM from NSCLC were randomly assigned to 30Gy WBRT with either concomitant gefitinib (GFT) 250mg/day continuously or temozolomide (TMZ) 75mg/m(2) for 21/28days.” PMID 22093943 ↗ Nov 2011 |
| Known as | IRESSA | “PURPOSE: This phase II trial assessed the activity and tolerability of a daily oral dose of 500 mg gefitinib (ZD1839, Iressa) in patients with recurrent or persistent...” PMID 16061871 ↗ Aug 200560“A Randomized, Open-Label, Parallel Group, International, Multicenter, Phase III Study of Oral ZD1839 (IRESSA®) Versus Intravenous Docetaxel (TAXOTERE®) in Patients With Locally...” NCT00076388 ↗ “A Randomised, Open Label, Parallel Group, Multi-Centre, Phase II Study of Progression Free Survival Comparing ZD1839 (IRESSA™) (250 MG Tablet) Versus Vinorelbine (30 MG/M2...” NCT00256711 ↗ “A Phase I/II Trial of Induction Chemotherapy Plus Gefitinib (Iressa) Followed by Concurrent Chemotherapy, Radiation Therapy, and Gefitinib (Iressa) For Patients With Locally...” NCT00193284 ↗ “Randomised Placebo-controlled Phase II Trial of Preoperative Therapy With Gefitinib (Iressa®/ZD1839) and Epirubicin-Cyclophosphamide in Patients With Primary Operable (T2-T3)...” NCT00239343 ↗ “An EORTC Randomized, Double Blind, Placebo-Controlled, Phase II Multi-Center Trial Of Anastrozole (Arimidex) In Combination With ZD 1839 (Iressa) Or Placebo In Patients With...” NCT00066378 ↗ “Phase II Pilot Study of Clinical Activity and Proteomic Pathway Profiling of the EGFR Inhibitor, ZD1839 (Iressa; Gefitinib), in Patients With Epithelial Ovarian Cancer or...” NCT00049556 ↗ “This study aims to determine effectiveness of Gefitinib (Iressa) in recurrent glioblastoma after standard treatment (surgery, radiationtherapy and at least a first line chemotherapy).” NCT00250887 ↗ “A Phase I/II Pilot Study of Bioimmunotherapy With IRESSA (Gefitinib) and Pegylated Interferon Alpha-2a for Patients With Unresectable/Metastatic Squamous Cell Carcinoma of the Skin” NCT00423397 ↗ “Maintenance ZD1839 (IRESSA®) Following Completion of Front Line, Platinum-Based, Double Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer” NCT00090675 ↗ “A Randomized Phase III Study of Follow Up With or Without Adjuvant Gefitinib (Iressa™) Following Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer” NCT00091156 ↗ “the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa) in combination with paclitaxel (Taxol) and external beam radiation therapy” PMID 19060587 ↗ Dec 2008 “Phase II Trial of Neoadjuvant Docetaxel and ZD 1839 (Iressa) Followed by Radical Prostatectomy in Patients With High Risk, Locally Advanced Prostate Cancer” NCT00242918 ↗ “A Phase I Study of ZD1839 (Iressa) in Combination With Irinotecan (Camptosar or CPT-11) and Vincristine in Pediatric Patients With Refractory Solid Tumors” NCT00186979 ↗ “The purpose of the study is to determine the efficacy of gefitinib (IressaTM) in combination with radiotherapy on patients with glioblastoma multiforme.” NCT00238797 ↗ “A Phase II Trial to Evaluate the Combination of ZD1839 (Iressa) and Fulvestrant (Faslodex®) in Patients With Advanced or Metastatic Breast Cancer” NCT00234403 ↗ “Multicenter Phase II Trial of Gefitinib (Iressa™) First Line Therapy Followed by Chemotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC)” NCT00217698 ↗ “Phase I/II study of gefitinib (Iressa(®)) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer.” PMID 25552401 ↗ Jan 2015 “A Phase II Study of ZD1839 (Iressa)in Chemotherapy Refractory Germ Cell Tumors Expressing Epidermal Growth Factor Receptor (EGFR)” NCT00198159 ↗ “75 patients received tyrosine kinase inhibitor daily. (dose: Osimertinib 80 mg/d, or Tarceva 150 mg/d, or Iressa 0.25 g/d.)” NCT03799094 ↗ “A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Treatment of Non-Small Cell Lung Cancer” NCT00238628 ↗ “Safety Study to Explore Combination of Gefitinib (ZD1839, Iressa) and Radiotherapy in Non-Metastatic Prostate Cancer” NCT00239291 ↗ “Gefitinib (EGFR Tyrosine Kinase Inhibitor, Iressa™) in Combination With BKM120, an Oral Pan-class I PI3K Inhibitor” NCT01570296 ↗ “Gefitinib (Iressa) in Combo With Chemoradiation in Patients With Locally Advanced Head & Neck Cancer” NCT00239304 ↗ “Adjuvant Therapy of Gefitinib (Iressa, ZD1839) in Patients With Resectable Hepatocellular Carcinoma” NCT00282100 ↗ “Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer” NCT00317772 ↗ “Cediranib (AZD2171) Plus Gefitinib (Iressa, ZD1839) With Cediranib Plus Placebo” NCT01310855 ↗ “ZD1839 (IRESSA®) in Previously Untreated Elderly Patients (≥70 Years Old)” NCT00231465 ↗ “Phase II of Gefitinib (IRESSA) Administered as First-line Treatment” NCT00198380 ↗ “A Study of IRESSA in Relapsed and Refractory Small Cell Lung Cancer” NCT00298688 ↗ “Study treatment will consist of Iressa (gefitinib) alone.” NCT00228488 ↗ “Intercalated administration of Iressa® (gefitinib)” NCT01502202 ↗ “Tyrosine Kinase Inhibitor gefitinib (Iressa)” NCT02321293 ↗ “Pemetrexed (ALIMTA) and Gefitinib (IRESSA®)” NCT01066195 ↗ “Drug: ZD1839 (IRESSA)” NCT01185158 ↗ “Iressa (Gefitinib)” NCT00234468 ↗ “Gefitinib (IRESSA)” NCT00891579 ↗ “Gefitinib (IRESSA)” NCT01363557 ↗ “gefitinib (Iressa)” NCT00080340 ↗ “Iressa (Gefitinib)” NCT00169221 ↗ “Iressa (Gefitinib)” NCT00234442 ↗ “ZD1839 (IRESSA™)” NCT00242762 ↗ “ZD1839 (IRESSA®)” NCT00185835 ↗ “ZD1839 (Iressa™)” NCT00059722 ↗ “ZD1839 (IRESSA)” NCT00006048 ↗ “ZD1839 (IRESSA)” NCT00195078 ↗ “ZD1839 (Iressa)” NCT00328562 ↗ |
| Known as | Iressa TM | “The purpose of the study is to determine the efficacy of gefitinib (IressaTM) in combination with radiotherapy on patients with glioblastoma multiforme.” NCT00238797 ↗2“A Phase I Study Of ZD1839 (Iressa TM), An Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, In Children With Refractory Solid Tumors” NCT00040781 ↗ “Gefitinib (Iressa TM) Arm - Gefitinib administration 250mg tablet once daily every 3 weeks” NCT00455936 ↗ |
| Known as | NSC-759856 | ChEMBL registry synonym — accepted as the source's own label CHEMBL939 ↗ |
| Known as | Yi Ruisha | “Gefitinib tablets (Yi Ruisha），First medication,250mg；” NCT03264794 ↗ |
| Known as | ZD 1839 | “PURPOSE: This phase II trial assessed the activity and tolerability of a daily oral dose of 500 mg gefitinib (ZD1839, Iressa) in patients with recurrent or persistent...” PMID 16061871 ↗ Aug 200553“A Randomized, Open-Label, Parallel Group, International, Multicenter, Phase III Study of Oral ZD1839 (IRESSA®) Versus Intravenous Docetaxel (TAXOTERE®) in Patients With Locally...” NCT00076388 ↗ “A Randomised, Open Label, Parallel Group, Multi-Centre, Phase II Study of Progression Free Survival Comparing ZD1839 (IRESSA™) (250 MG Tablet) Versus Vinorelbine (30 MG/M2...” NCT00256711 ↗ “The purpose of this study is to determine if the addition of ZD1839 Iressa™ to standard treatment with Casodex® (bicalutamide) for locally advanced prostate cancer can detect a...” NCT00319787 ↗ “Randomised Placebo-controlled Phase II Trial of Preoperative Therapy With Gefitinib (Iressa®/ZD1839) and Epirubicin-Cyclophosphamide in Patients With Primary Operable (T2-T3)...” NCT00239343 ↗ “A Phase II Open-Label Multicentre Study Of The Efficacy Of ZD1839 (IRESSA™) In Combination With Irradiation Followed By Chemotherapy In Patients With Inoperable Stage III Non...” NCT00333294 ↗ “An EORTC Randomized, Double Blind, Placebo-Controlled, Phase II Multi-Center Trial Of Anastrozole (Arimidex) In Combination With ZD 1839 (Iressa) Or Placebo In Patients With...” NCT00066378 ↗ “Over the last three years, the FDA has approved two drugs for salvage treatment of NSCLC, gefitinib (Iressa ®, formerly known as ZD1839) and erlotinib (Tarceva ®, formerly...” NCT00809237 ↗ “Phase II Pilot Study of Clinical Activity and Proteomic Pathway Profiling of the EGFR Inhibitor, ZD1839 (Iressa; Gefitinib), in Patients With Epithelial Ovarian Cancer or...” NCT00049556 ↗ “This is a phase II window study of the combination of ZD1839 (gefitinib) and irinotecan in children with high-risk neuroblastoma followed by standard induction chemotherapy” NCT00135135 ↗ “Combination Anastrozole-ZD1839 (Gefitinib, IRESSA™) in Postmenopausal Patients With Estrogen Receptor (ER) and/or Progesterone Receptor (PgR) Metastatic Breast Cancer” NCT00077025 ↗ “A Phase I Study of ZD1839 (Iressa) in Combination With Irinotecan (Camptosar or CPT-11) and Vincristine in Pediatric Patients With Refractory Solid Tumors” NCT00186979 ↗ “A Phase I Study Of ZD1839 (Iressa TM), An Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, In Children With Refractory Solid Tumors” NCT00040781 ↗ “A Phase II Trial to Evaluate the Combination of ZD1839 (Iressa) and Fulvestrant (Faslodex®) in Patients With Advanced or Metastatic Breast Cancer” NCT00234403 ↗ “A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Treatment of Non-Small Cell Lung Cancer” NCT00238628 ↗ “Safety Study to Explore Combination of Gefitinib (ZD1839, Iressa) and Radiotherapy in Non-Metastatic Prostate Cancer” NCT00239291 ↗ “Gefitinib (ZD1839) may stop the growth of cancer cells by blocking the enzymes necessary for their growth.” NCT00057941 ↗ “Adjuvant Therapy of Gefitinib (Iressa, ZD1839) in Patients With Resectable Hepatocellular Carcinoma” NCT00282100 ↗ “small molecules such as gefitinib (Iressa [ZD1839]; AstraZeneca, Wilmington, DE).” NCT00173875 ↗ “Cediranib (AZD2171) Plus Gefitinib (Iressa, ZD1839) With Cediranib Plus Placebo” NCT01310855 ↗ “Gefitinib (ZD1839), a Selective EGFR Tyrosine Kinase Inhibitor” NCT00820417 ↗ “ZD1839 (gefitinib)” NCT00357734 ↗ “ZD1839 (IRESSA®)” NCT00185835 ↗ “Iressa (ZD1839)” NCT00181688 ↗ “Iressa (ZD1839)” NCT00215202 ↗ |
| Known as | ZD1839, gefitinib (Iressa) | “ZD1839, gefitinib (Iressa)” NCT00052169 ↗ |
| Action | Inhibit | “ZD 1839 may interfere with the growth factor and stop the tumor from growing.” NCT00006048 ↗ |
| Modality | Small molecule | “An Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI)” NCT00052208 ↗ |
| Route | Oral | “higher dose oral ZD 1839” NCT00006048 ↗ |
| Target | EGFR | “In tumor samples, gefitinib did not inhibit activation of its proximal target, EGFR.” PMID 16361624 ↗ Dec 2005 |